An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Category Primary study
JournalCancer Treatment Communications
Year 2015
This article has no abstract
Epistemonikos ID: 5e0450d02ae38299a04e69d5d4c68c41a13be939
First added on: Feb 07, 2025